Get the Stockscreener App
0.00
100.00%
-0.25
Eagle Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.25
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
$257.55M
Net Income/Loss:
$11.95M
P/E Ratio:
0.00
EPS:
0.91
Net Cash Flow:
$-9.39M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-93.26%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$3.725
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Compare EGRX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EGRX
Eagle Pharmaceuticals Inc
|
0.00 | 0 | 257.55M | 11.95M | -9.39M | 0.91 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-01-18 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Mar-21-18 | Reiterated | Mizuho | Underperform |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Reiterated | Mizuho | Underperform |
| Jul-27-17 | Reiterated | Mizuho | Underperform |
| Jul-27-17 | Reiterated | RBC Capital Mkts | Outperform |
| May-09-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-09-17 | Downgrade | Mizuho | Neutral → Underperform |
| Nov-16-16 | Downgrade | Mizuho | Buy → Neutral |
| Nov-03-16 | Upgrade | Mizuho | Neutral → Buy |
| Nov-03-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-26-16 | Reiterated | Mizuho | Buy |
| Aug-16-16 | Reiterated | Mizuho | Neutral |
| Jun-20-16 | Downgrade | Mizuho | Buy → Neutral |
| May-10-16 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-18-16 | Reiterated | Mizuho | Buy |
| Feb-26-16 | Reiterated | Mizuho | Buy |
| Dec-09-15 | Initiated | Mizuho | Buy |
| Jul-29-15 | Reiterated | Piper Jaffray | Overweight |
View All
Eagle Pharmaceuticals Inc Stock (EGRX) Latest News
Eagle Point Announces Strong Year of Performance with 2025 Year-End Review - Yahoo Finance
American Eagle to Participate in PDAC 2026 and Ore Day VIP Investor Lunch - Yahoo Finance
EDGAR Filing Documents for 0001104659-19-033601 - SEC.gov
Eagle Health Investments LP Sells 22,400 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Eagle Health Investments LP Sells 84,600 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Wall Street Bullish on Agnico Eagle Mines (AEM) After FQ4 Results - Yahoo Finance
Is Trending Stock American Eagle Outfitters, Inc. (AEO) a Buy Now? - Yahoo Finance
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation - Eagle-Tribune
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development - eagletribune.com
Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Agnico Eagle Mines Limited $AEM Shares Acquired by Campbell & CO Investment Adviser LLC - Defense World
Eagle Pharmaceuticals Announces Divestiture Of Barhemsys - TradingView
Eagle Pharmaceuticals Announces Divestiture of Barhemsys - The Manila Times
Only FDA-approved post-surgery nausea drug shifts to new owner - Stock Titan
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound - Eagle-Tribune
GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies - Yahoo Finance
Top Research Reports for JPMorgan Chase, RTX & Applied Materials - TradingView
Aadi Bioscience (NASDAQ:AADI) vs. Eagle Pharmaceuticals (NASDAQ:EGRX) Head to Head Survey - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Crosses Above Fifty Day Moving Average – Here’s What Happened - Defense World
Eagle Point Credit Company Inc. Announces Full Redemption of the 8.00% Series F Term Preferred Stock Due 2029 - Yahoo Finance
Pemetrexed Market Industry Forecast 2025-2032 Highlights - openPR.com
HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - The Malaysian Reserve
Talon Metals to Acquire Lundin Mining's Eagle Mine and Humboldt Mill Operations, Creating a Multi-Asset U.S. Nickel-Copper Company - Yahoo Finance
Amphastar Announces FDA Approval for Teriparatide Injection - Eagle-Tribune
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Eagle-Tribune
DHIL Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Diamond Hill Investment Group, Inc. is Fair to Shareholders - Business Wire
Critical Review: NexImmune (NASDAQ:NEXI) and Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - The AI Journal
Reviewing Eagle Pharmaceuticals (NASDAQ:EGRX) and Bio-Path (NASDAQ:BPTH) - Defense World
EB Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Eventbrite, Inc. is Fair to Shareholders - Business Wire
Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday - Benzinga
Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis - Seeking Alpha
Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3 - Insider Monkey
ACA Pharma Announces Major Expansion of RYANODEX® Territory Outside the United States - NEWS CHANNEL NEBRASKA- Northeast
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Passes Below 200 Day Moving Average – What’s Next? - Defense World
Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality (NASDAQ:VNDA) - Seeking Alpha
Indian Society of Anaesthesiologists Hosts Nationwide Launch of Ryanodex® in India - PRWeb
ACA Pharma Announces 2026 China NPP Group Procurement Priority List for Orphan and Clinically Urgent Drugs - PRWeb
Antiemetics Drugs Market Size Worth USD 30.63 Billion by 2034 - BioSpace
U.S. Vasopressin Market Poised for Transformation with - openPR.com
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan - The Manila Times
Eagle Pharma (OTCMKTS: EGRX) extends stockholder rights plan to 2026; $20 exercise - Stock Titan
Giant Eagle opens new pharmacy in Mt. Washington, filling gap left by Rite Aid - WTAE
Total debt per share of EAGLE PHARMACEUTICALS INC – OTC:EGRX - TradingView
Revenue per share of Eagle Pharmaceuticals, Inc. – LS:A1XEDS - TradingView
Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East - PR Newswire
Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders - The Manila Times
Eagle Pharmaceuticals Inc Stock (EGRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.77%
Cap:
|
Volume (24h):